.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR05_ZidovudineLamivudineAndN.ZidovudineLamivudineAndN .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR05_ZidovudineLamivudineAndN.ZidovudineLamivudineAndN| name: | ZidovudineLamivudineAndNevirapine | |
| ATC code: | J05AR05 | route: | oral |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 1.6 | L |
| clearance: | 0.8 | L/h/kg |
| other parameters in model implementation | ||
Zidovudine, lamivudine, and nevirapine is a fixed-dose combination antiretroviral medication used for the treatment of HIV infection. It combines two nucleoside reverse transcriptase inhibitors (zidovudine and lamivudine) with a non-nucleoside reverse transcriptase inhibitor (nevirapine). This combination is approved and in use worldwide, especially in resource-limited settings as a first-line therapy.
Pharmacokinetic parameters in HIV-infected adults under steady-state conditions with oral administration of the fixed-dose combination tablet.